Archive for July, 2017

Three Strikes and You’re Out – Unless…

0 | By Michael A. Robinson

Three strikes and you’re out, right?

Not in my league – where we’ve got instant replay and it’s clear the umpire missed the call.

In this case we’ve got three “umpires” – and after checking the “tape” I’m convinced they all need new glasses.

Here’s what I’m talking about…

Between April 4 and 27 – after the end of the

Continue Reading

You Won’t Sweat Your Next Gut Check With These Three Tactics

0 | By Michael A. Robinson

The tech-centric Nasdaq Composite index hit a new all-time high on July 20. It was the Nasdaq’s 10th straight winning session.

The rest of the market is doing well, too. Last week marked the 27th new high for the S&P 500 this year, making 2017 one of the index’s best years in decades.

This historic bull market is now entering its ninth year.

And so, I know that many of you have been holding onto your cash and hoping for a selloff to lower prices.

You’re not alone. The Wall Street Journal reports that fund managers have increased their cash holdings by 10% this month, to 4.9% of assets.

I understand that impulse.

But I hope you’re not so inclined.

Because if you sat out the year so far, you left a lot of money on the table.

You know that now.

I’m here to tell you today that it’s still not too late to make your move.

But I know that will take a “gut check.”

That’s why I’m showing you three tools that will make that “gut check” easier.

They’ll keep you in the market – and give you the confidence you need to keep making big gains with tech stocks…

At the risk of sounding like a broken record, I can’t say it often enough – the Road to Wealth Is Paved by Tech. And I can prove it…

Since the bull market began on March 9, 2009, the Nasdaq is up 346%. That’s more than 50% better than the S&P’s return over the period.

And it’s all because of the new Convergence Economy we’ve been talking about here for some time now. These days, every business is a tech business, meaning the sector will beat the overall market for years to come.

Having said that, however, it bears noting that no stock, sector, or market rises in a straight line forever. Sooner or later, the market will lose steam.

Let me be clear. I see plenty of upside ahead through the end of 2017. And it bears repeating this is not the time to horde cash and hope for better prices.

Instead, you want to be in tech stocks. And if you use these three Gut Check Tools, you can invest with confidence – and protect your market-crushing gains.

Take a look…

Can Rising eBay Actually Deliver to Shareholders?

1 | By Michael A. Robinson

On the surface, eBay Inc. seems to be flying again with 25% stock gains so far this year and 171 million registered users behind it. But should investors buy on eBay now? Our own Michael A. Robinson talks to CNBC‘s The Rundown about whether it actually has a plan to execute on the expectations that drove the stock price rise or to compete with the likes of Amazon Prime.

Huge Arenas, Global Audiences, Big Profits

0 | By Michael A. Robinson

There’s not a major sports league in the world today that wouldn’t love to undergo 138% growth in just four years.

We’re talking a total of 238 million viewers around the world for a “sport” that didn’t really hit its stride until 2010.

To cash in on this fast-growing trend, a group of owners from the National Football League, National Basketball Association, and Major League Baseball recently invested more than $140 million to start their own teams.

And if the players look more like computer geeks than athletes, it’s because that’s just what they are. In the new field of eSports, teams duel it out over computer games while fans watch online or at major arenas.

Here’s the thing. Though the field is new, it’s already ripe for disruption due to the immersive experience of virtual reality (VR).

Today, I’m going to reveal a VR firm that offers us a rare Convergence Economy play on the emerging lucrative mix of sports and digital tech.

Let’s get started…

When AI Meets Biotech, the Results Are Amazing – and Profitable

1 | By Michael A. Robinson

In biotech, one thing isn’t going to change.

The treatment that makes up 90% of the pharmaceutical market – good, old-fashioned small molecules created in the laboratory – isn’t going anywhere.

Yes, incredibly innovative treatments like T-cell therapy, microbiome therapies, and CRISPR gene editing are all having a huge impact on healthcare.

But we use small, synthetic molecules to create everything from aspirin and corticosteroids to sofosbuvir (Sovaldi) and ivacaftor (Kalydeco) – and we’ll keep doing so for a long time to come.

The small molecule technique dates back to the 1890s, but that doesn’t mean innovation cannot happen within that field. Scientists are hard at work in the labs, creating cutting-edge drugs, often tailored to treat a very specific disease or subset of patients.

Meanwhile, I’ve turned up a small British company that’s using its artificial intelligence platform to discover promising small molecule treatments faster – and cheaper – than ever before.

I call it biointelligence.

It’s a perfect illustration of the “Convergence Economy” we talk so much about here. By combining two or more fields of tech – in this case biotech and AI – it’s like a formula in which 1 + 1 = 3… and often a lot more that.

Today, we’re going to learn all about this tiny company and its brand-new biointelligence technology.

This company is privately held – so if you ask, Wall Street will say you can’t invest in it.

But I’ve a way you can.

In fact, I’ve found two ways.

Both of them will lead you to outsized returns – and hefty dividends.

Let’s take a look…

Every Time Trump Rips Into NATO, This Stock Soars

2 | By Michael A. Robinson

We’ve talked about some truly revolutionary tech developments rocking the entire defense sector right now, like laser weapons, advanced drones, helicopters, battlefield AI, and global awareness.

It all sounds very sci-fi, but it’s happening now (and making us some serious money).

I want to talk about something a little less flashy but perhaps even more important to keeping our armed forces effective when boots are on the ground.

It’s not headline-grabbing, and you certainly couldn’t call it “state of the art.” In fact, at less than $5 billion, it’s a relatively small, overlooked niche in one of the world’s most lucrative, high-profile sectors.

That’s just one of the reasons why I love it right now.

The upside is huge… market-crushing.

And it’s all likely headed to this European company with a U.S. presence

They Own 6% of the Stock Market

2 | By Michael A. Robinson

There’s an under-the-radar reason why the stock market keeps rallying despite some mediocre economic numbers, constant “noise” out of Washington, and plenty of overheated valuations.

And while it’s a bit hidden, it’s huge.

In fact, it owned 6% of the U.S. stock market in the first quarter.

And it keeps gobbling things up.

It bought $98 billion in U.S. stocks during the first three months of the year – and that puts it on pace to surpass its total purchases for 2015 and ’16 combined.

I’m talking about exchange-traded funds (ETFs) and Main Street investors’ big appetite for passive investments.

Those investors keep putting more money into funds they can then forget about – and the market keeps rising.

Now you could join them and buy some passive index funds.

But that’s not what we do here. We’re in search of investments on the Frontier – ones that will double, triple… even quadruple our money.

So let’s get active and go in search of three ETFs that will get us to that Frontier.

All three will continue to double the market’s return – and line your pockets – for years to come…

Three Biotech Bargains to Buy Right Now

5 | By Michael A. Robinson

Back in October, I did something crazy.

That’s when I told the paid-up members of my Radical Technology Profits trading service to buy a small-cap biotech stock.

Here’s why that move was a bit nuts.

At the time, it looked like Hillary Clinton would soon enter in the White House and clamp down on drug prices – and so the biopharmaceutical sector was deeply out of favor.

Turns out, however, our crazy bet paid off.

Despite his campaign rhetoric, President Donald Trump has pulled back from his own fiery rhetoric about drug-price caps.

That helped pushed biotech and drug stocks into a big uptrend.

And my paid-up members made peak gains of 116% – in just over eight months.

Today, things have changed – and investing in biopharma stocks is generally seen as a smart move. However, that means a lot of these shares have been bid up, and your best move is to buy big winners at deep discounts.

But to do that, you have to know how to find those deals.

I do.

Today I’ll show you how you can, too.

And I’ll reveal the three best Biotech Bargains out there right now

All three have triple-digit gains potential…